🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

265 results for “LG” Clear

  1. filgrastim

    Solid Biosciences

    Lymphoma

    phase 3 mab active

    2 trials

  2. filgrastim

    Children's Hospital of Fudan University

    Neuroblastoma

    phase 3 mab completed

    1 trial

  3. filgrastim

    Solid Biosciences

    Lung Cancer

    phase 3 mab active

    1 trial

  4. filgrastim

    Hospital Authority, Hong Kong

    Brain and Central Nervous System Tumors

    phase 3 mab completed

    2 trials

  5. lipegfilgrastim

    Teva Pharma GmbH

    Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia

    phase 3 small molecule completed

    1 trial

  6. pegfilgrastim

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 mab active

    1 trial

  7. placebo

    Jazz Pharmaceuticals Ireland Limited

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

  8. zilganersen

    IONIS PHARMACEUTICALS INC

    Alexander Disease

    phase 3 small molecule active

    1 trial

  9. ACE-536

    Celgene Europe Limited

    Beta-Thalassemia

    phase 2 small molecule active

    1 trial

  10. ADSTILADRIN

    Ferring Pharmaceuticals

    Low-grade upper track urothelial carcinoma (LG-UTUC)

    phase 2 small molecule active

    1 trial

  11. ALG-000184

    Aligos Therapeutics

    Chronic Hepatitis B Infection

    phase 2 small molecule active

    1 trial

  12. ALG-000184, ALG-000184 Placebo, Tenofovir Disoproxil Placebo, Tenofovirdisoproxil Amarox 245 mg Filmtabletten

    Aligos Therapeutics

    Chronic Hepatitis B Virus Infection

    phase 2 small molecule active

    1 trial

  13. ALG-055009

    Aligos Therapeutics

    NASH

    phase 2 small molecule completed

    1 trial

  14. ALG.APV-527

    Aptevo Therapeutics

    Solid Tumor

    phase 2 small molecule active

    1 trial

  15. APREPITANT, IDARUBICIN HYDROCHLORIDE, LEVOCARNITINE, CYCLOPHOSPHAMIDE, GRANISETRON, SALBUTAMOL, GANCICLOVIR, AMPHOTERICIN B, ALLOPURINOL, DARZALEX 1800 mg solution for injection, HUMAN FIBRINOGEN, CYTARABINE, DEXAMETHASONE SODIUM PHOSPHATE, VINCRISTINE SULFATE, PARACETAMOL, MONTELUKAST, FILGRASTIM, CYTARABINE, LEVOFLOXACIN, RASBURICASE, METHOTREXATE, HYDROCORTISONE, FOSCARNET, METHYLPREDNISOLONE SODIUM SUCCINATE, LENOGRASTIM, PEGASPARGASE, DEXAMETHASONE SODIUM PHOSPHATE, MICAFUNGIN, ACICLOVIR, CHLORPHENAMIN

    Fondazione Telethon ETS

    Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  16. ARK-E021 5%

    VYNE Therapeutics

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  17. Actrapid 100 international units/ml solution for injection in vial, Natriumklorid Fresenius Kabi, 9 mg/ml, infusionsvätska, lösning, SODIUM CHLORIDE, Natriumklorid Fresenius Kabi 9 mg/ml, spädningsvätska för parenteral användning, Albumin Baxalta 200 g/l infusionsvätska, lösning, Glucos Fresenius Kabi 200 mg/ml infusionsvätska, lösning, A24110He

    Lacuna Pharma Pty Ltd

    Moderate to severe hypertriglyceridemia

    phase 2 small molecule active

    1 trial

  18. Alkotinib Capsules

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    ALK-positive Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  19. Alnuctamab, Alnuctamab, CC-92480 0.3 mg, CC-92480 0.4 mg, CC-92480 0.6 mg, DEXAMETHASONE, CC-92480 0.2 mg

    Celgene Europe Limited

    Relapsed and/or Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  20. Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet

    Lacuna Pharma Pty Ltd

    Polymyalgia rheumatica

    phase 2 small molecule active

    1 trial

  21. Azacitidine 150mg tablet, Azacitidine 200mg tablet: film- coated tablet, azacitidine, PEMBROLIZUMAB, azacitidine

    Celgene Europe Limited

    Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  22. CC-92480, Dexamethason acis 8 mg Tabletten, Dexamethason 8 mg JENAPHARM®, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480, Dexamethason 4 mg JENAPHARM®, Dexamethason-ratiopharm® 4 mg Tabletten

    Celgene Europe Limited

    Relapsed and refractory multiple myeloma (RRMM)

    phase 2 small molecule active

    1 trial

  23. CC-97489, CC-97489, CC-97489 1mg , CC-97489 3mg

    Celgene Europe Limited

    Multiple Sclerosis Spasticity

    phase 2 small molecule active

    1 trial

  24. CD19-Targeted NEX-T CAR T, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, FLUDARABINE, CYCLOPHOSPHAMIDE

    Celgene Europe Limited

    Lupus Nephritis, Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources